Cargando…

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study

BACKGROUND: Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors can potentially reduce the risk of cardiovascular mortality in patients with type 2 diabetes mellitus (T2DM). However, there is little or no information on the therapeutic effects of SGLT2 inhibitors on the pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shigiyama, Fumika, Kumashiro, Naoki, Miyagi, Masahiko, Ikehara, Kayoko, Kanda, Eiichiro, Uchino, Hiroshi, Hirose, Takahisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500953/ https://www.ncbi.nlm.nih.gov/pubmed/28683796 http://dx.doi.org/10.1186/s12933-017-0564-0

Ejemplares similares

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
por: Shigiyama, Fumika, et al.
Publicado: (2016)

Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study
por: Shigiyama, Fumika, et al.
Publicado: (2018)

Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium–glucose cotransporter 2 inhibitor: A randomized, open‐label, prospective study
por: Kanazawa, Ken, et al.
Publicado: (2019)

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
por: Fuchigami, Ayako, et al.
Publicado: (2020)

Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well‐controlled type 2 diabetes: A 24‐week randomized controlled trial
por: Ando, Yasuyo, et al.
Publicado: (2021)

A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study
por: Hiruma, Shigenori, et al.
Publicado: (2021)

Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial
por: Iga, Ryo, et al.
Publicado: (2017)

Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin’s Effect to Sitagliptin on Cardiac Fat Accumulation/Function in Patients with Type 2 Diabetes
por: Shigiyama, Fumika, et al.
Publicado: (2019)

Successful Treatment of Amiodarone-induced Thyrotoxicosis Type 1 in Combination with Methimazole and Potassium Iodide in a Patient with Hashimoto's Thyroiditis
por: Katoh, Daisuke, et al.
Publicado: (2019)

Characteristics of hepatic insulin‐sensitive nonalcoholic fatty liver disease
por: Shigiyama, Fumika, et al.
Publicado: (2017)

Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm
por: Miyagi, Masahiko, et al.
Publicado: (2018)

A Real-World, Prospective, Non-interventional Study of Adults with T2D Switching to IDegAsp from Glargine U100 or U300 in Japan
por: Shigiyama, Fumika, et al.
Publicado: (2021)

A Case of Acute-Onset Type 1 Diabetes Mellitus with Diabetic Ketoacidosis Triggered by COVID-19
por: Zenri, Mariko, et al.
Publicado: (2023)

Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus
por: Kong, Sung Hye, et al.
Publicado: (2019)

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Li, Feng-fei, et al.
Publicado: (2016)

Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus
por: Yue, Wen-Sheng, et al.
Publicado: (2011)

Impact of glycemic control on the association of endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus
por: Chen, Shuai, et al.
Publicado: (2021)

Acute suppurative thyroiditis in infected thyroid cyst in an adult patient under hemodialysis
por: Igarashi, Hiroyuki, et al.
Publicado: (2017)

Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
por: Sposito, Andrei C., et al.
Publicado: (2021)

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
por: Soga, Fumitaka, et al.
Publicado: (2018)

Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure
por: Tanaka, Hidekazu, et al.
Publicado: (2020)

The effect of dapagliflozin treatment on epicardial adipose tissue volume
por: Sato, Takao, et al.
Publicado: (2018)

Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity
por: Ulusan, Sebahat, et al.
Publicado: (2023)

Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function
por: Ma, Fei, et al.
Publicado: (2022)

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)
por: Nakajima, Hiroki, et al.
Publicado: (2018)

Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus
por: Yoshimura, Yuta, et al.
Publicado: (2023)

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
por: Solini, Anna, et al.
Publicado: (2017)

Giant Cavernous Hemangioma of the Adrenal Gland in an Elderly Patient
por: Hashimoto, Ayana, et al.
Publicado: (2017)

Retracted: Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function
por: Markers, Disease
Publicado: (2023)

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2015)

Vascular endothelial microparticles-incorporated microRNAs are altered in patients with diabetes mellitus
por: Jansen, Felix, et al.
Publicado: (2016)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Association of glycemic variability with left ventricular diastolic function in type 2 diabetes mellitus
por: Yokota, Shun, et al.
Publicado: (2019)

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
por: Lee, Dustin M., et al.
Publicado: (2018)

Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus
por: Ichikawa, Ryoko, et al.
Publicado: (2013)

Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Response: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
por: Kong, Sung Hye, et al.
Publicado: (2019)

Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury
por: Lahnwong, Sarayut, et al.
Publicado: (2020)

Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)
por: Kinguchi, Sho, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h0tdnvi4tfikglrus983co0mh7